Final results of a phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results